Real Time Insider Transaction Data
Real Time Insider buys and sells Data - Insider Trades - Insider Transactions - Insider Trading Data - SEC Form 4 Data
Total | Transactions | Amount |
Buys | 1831 | $1,874,596,842 |
Sells | 6733 | $16,255,303,244 |
Security | Reporting Name | Relationship | Purchase/Sale | Shares | Price $ | D/I | ||||
14 Jun 2024 16:46 | AGYS | AGILYSYS INC | MAK CAPITAL ONE LLC | Affiliate of Director | 12 Jun 2024 | Sale | 33,933 | 92.7502 | 3,147,293 | I |
11 Jun 2024 17:04 | AGYS | AGILYSYS INC | MAK CAPITAL ONE LLC | Affiliate of Director | 11 Jun 2024 | Sale | 14,265 | 91.5926 | 1,306,568 | I |
11 Jun 2024 17:04 | AGYS | AGILYSYS INC | MAK CAPITAL ONE LLC | Affiliate of Director | 10 Jun 2024 | Sale | 25,747 | 92.8845 | 2,391,497 | I |
11 Jun 2024 17:04 | AGYS | AGILYSYS INC | MAK CAPITAL ONE LLC | Affiliate of Director | 07 Jun 2024 | Sale | 66,795 | 93.795 | 6,265,037 | I |
06 Jun 2024 17:04 | AGYS | AGILYSYS INC | MAK CAPITAL ONE LLC | Affiliate of Director | 06 Jun 2024 | Sale | 28,018 | 93.0715 | 2,607,677 | I |
06 Jun 2024 17:04 | AGYS | AGILYSYS INC | MAK CAPITAL ONE LLC | Affiliate of Director | 05 Jun 2024 | Sale | 28,429 | 95.4379 | 2,713,204 | I |
06 Jun 2024 17:04 | AGYS | AGILYSYS INC | MAK CAPITAL ONE LLC | Affiliate of Director | 04 Jun 2024 | Sale | 28,941 | 92.758 | 2,684,509 | I |
28 Jun 2024 17:18 | AI | C3.ai Inc | LATH HITESH | CHIEF FINANCIAL OFFICER | 27 Jun 2024 | Sale | 3,005 | 27.56 | 82,818 | D |
02 Jul 2024 16:15 | AIG | AMERICAN INTERNATIONAL GROUP Inc | INGLIS JOHN C | Director | 28 Jun 2024 | Purchase | 6.9 | 74.8891 | 517 | D |
14 Jun 2024 16:07 | AIG | AMERICAN INTERNATIONAL GROUP Inc | ZAFFINO PETER | Chairman & CEO | 12 Jun 2024 | Sale | 199,099 | 74.52 | 14,836,857 | D |
14 Jun 2024 16:07 | AIG | AMERICAN INTERNATIONAL GROUP Inc | ZAFFINO PETER | Chairman & CEO | 12 Jun 2024 | Sale | 901 | 75 | 67,575 | D |
03 Jul 2024 18:27 | AIP | Arteris Inc | ALPERN PAUL L | VP and General Counsel | 02 Jul 2024 | Sale | 1,006 | 6.9795 | 7,021 | D |
03 Jul 2024 18:27 | AIP | Arteris Inc | ALPERN PAUL L | VP and General Counsel | 02 Jul 2024 | Sale | 1,176 | 6.9795 | 8,208 | D |
03 Jul 2024 18:27 | AIP | Arteris Inc | ALPERN PAUL L | VP and General Counsel | 01 Jul 2024 | Sale | 1,250 | 7.2429 | 9,054 | D |
03 Jul 2024 18:27 | AIP | Arteris Inc | ALPERN PAUL L | VP and General Counsel | 01 Jul 2024 | Sale | 10,000 | 7.2389 | 72,389 | D |
03 Jul 2024 18:27 | AIP | Arteris Inc | MOLL LAURENT R | Chief Operating Officer | 02 Jul 2024 | Sale | 1,880 | 6.9795 | 13,121 | D |
03 Jul 2024 18:27 | AIP | Arteris Inc | MOLL LAURENT R | Chief Operating Officer | 02 Jul 2024 | Sale | 1,921 | 6.9795 | 13,408 | D |
03 Jul 2024 18:27 | AIP | Arteris Inc | MOLL LAURENT R | Chief Operating Officer | 01 Jul 2024 | Sale | 603 | 7.51 | 4,529 | D |
03 Jul 2024 18:28 | AIP | Arteris Inc | JANAC K CHARLES | President and CEO, 10% | 03 Jul 2024 | Sale | 9,168 | 7.2284 | 66,270 | D |
03 Jul 2024 18:28 | AIP | Arteris Inc | JANAC K CHARLES | President and CEO, 10% | 02 Jul 2024 | Sale | 2,760 | 6.9795 | 19,263 | D |
03 Jul 2024 18:28 | AIP | Arteris Inc | JANAC K CHARLES | President and CEO, 10% | 02 Jul 2024 | Sale | 2,760 | 6.9795 | 19,263 | D |
03 Jul 2024 18:28 | AIP | Arteris Inc | JANAC K CHARLES | President and CEO, 10% | 01 Jul 2024 | Sale | 4,583 | 7.2401 | 33,181 | D |
03 Jul 2024 18:28 | AIP | Arteris Inc | HAWKINS NICHOLAS B. | VP and Chief Financial Officer | 03 Jul 2024 | Sale | 2,462 | 7.2258 | 17,790 | D |
03 Jul 2024 18:28 | AIP | Arteris Inc | HAWKINS NICHOLAS B. | VP and Chief Financial Officer | 02 Jul 2024 | Sale | 1,484 | 6.9795 | 10,358 | D |
03 Jul 2024 18:28 | AIP | Arteris Inc | HAWKINS NICHOLAS B. | VP and Chief Financial Officer | 02 Jul 2024 | Sale | 1,504 | 6.9795 | 10,497 | D |
11 Jun 2024 21:49 | AIP | Arteris Inc | VIANA ANTONIO J | Director | 10 Jun 2024 | Sale | 2,836 | 8.1026 | 22,979 | I |
10 Jun 2024 16:16 | AIP | Arteris Inc | VIANA ANTONIO J | Director | 07 Jun 2024 | Sale | 26,919 | 7.8545 | 211,435 | I |
06 Jun 2024 19:15 | AIP | Arteris Inc | MOLL LAURENT R | Chief Operating Officer | 04 Jun 2024 | Sale | 611 | 7.8125 | 4,773 | D |
06 Jun 2024 19:15 | AIP | Arteris Inc | HAWKINS NICHOLAS B. | VP and Chief Financial Officer | 05 Jun 2024 | Sale | 722 | 7.72 | 5,574 | D |
06 Jun 2024 19:15 | AIP | Arteris Inc | HAWKINS NICHOLAS B. | VP and Chief Financial Officer | 04 Jun 2024 | Sale | 437 | 7.8125 | 3,414 | D |
06 Jun 2024 19:15 | AIP | Arteris Inc | JANAC K CHARLES | President and CEO, 10% | 04 Jun 2024 | Sale | 2,061 | 7.6265 | 15,718 | D |
06 Jun 2024 19:15 | AIP | Arteris Inc | JANAC K CHARLES | President and CEO, 10% | 04 Jun 2024 | Sale | 1,242 | 7.8125 | 9,703 | D |
07 Jun 2024 16:19 | AIRI | AIR INDUSTRIES GROUP | MELLUZZO LUCIANO M | President | 06 Jun 2024 | Purchase | 11,082 | 3.635 | 40,283 | D |
18 Jun 2024 18:51 | AJG | Arthur J. Gallagher & Co. | HUDSON SCOTT R | Vice President | 18 Jun 2024 | Sale | 10,000 | 263.453 | 2,634,530 | D |
18 Jun 2024 18:48 | AJG | Arthur J. Gallagher & Co. | BAY WALTER D. | General Counsel | 18 Jun 2024 | Sale | 8,303 | 262.742 | 2,181,547 | D |
17 Jun 2024 16:33 | AKAM | AKAMAI TECHNOLOGIES INC | BLUMOFE ROBERT | Chief Technology Officer | 14 Jun 2024 | Sale | 219 | 88.34 | 19,346 | D |
14 Jun 2024 17:37 | AKAM | AKAMAI TECHNOLOGIES INC | BLUMOFE ROBERT | Chief Technology Officer | 14 Jun 2024 | Sale | 3,000 | 88.34 | 265,020 | D |
02 Jul 2024 18:55 | AKRO | Akero Therapeutics Inc | YOUNG JONATHAN | Chief Operating Officer | 01 Jul 2024 | Sale | 5,000 | 23.404 | 117,020 | D |
13 Jun 2024 18:09 | AKRO | Akero Therapeutics Inc | WHITE WILLIAM RICHARD | Chief Financial Officer | 11 Jun 2024 | Sale | 2,831 | 22.64 | 64,094 | D |
13 Jun 2024 18:11 | AKRO | Akero Therapeutics Inc | YALE CATRIONA | Chief Development Officer | 11 Jun 2024 | Sale | 2,825 | 22.641 | 63,961 | D |
13 Jun 2024 18:13 | AKRO | Akero Therapeutics Inc | YOUNG JONATHAN | Chief Operating Officer | 11 Jun 2024 | Sale | 2,516 | 22.641 | 56,965 | D |
13 Jun 2024 18:04 | AKRO | Akero Therapeutics Inc | LAMY PATRICK | Senior VP, Commercial Strategy | 11 Jun 2024 | Sale | 569 | 22.641 | 12,883 | D |
13 Jun 2024 18:06 | AKRO | Akero Therapeutics Inc | ROLPH TIMOTHY | Chief Scientific Officer | 11 Jun 2024 | Sale | 2,380 | 22.641 | 53,886 | D |
13 Jun 2024 18:01 | AKRO | Akero Therapeutics Inc | CHENG ANDREW | President and CEO | 11 Jun 2024 | Sale | 7,894 | 22.641 | 178,728 | D |
12 Jun 2024 16:01 | AKYA | Akoya Biosciences Inc | MCKELLIGON BRIAN | President and CEO | 11 Jun 2024 | Sale | 7,500 | 2.084 | 15,630 | D |
07 Jun 2024 21:56 | AKYA | Akoya Biosciences Inc | MCKELLIGON BRIAN | President and CEO | 06 Jun 2024 | Sale | 7,500 | 2.0085 | 15,064 | D |
06 Jun 2024 18:07 | ALGT | Allegiant Travel CO | WILSON ROBERT PAUL III | EVP and CIO | 04 Jun 2024 | Sale | 750 | 53 | 39,750 | D |
03 Jul 2024 17:37 | ALHC | Alignment Healthcare Inc | JOYCE CHRISTOPHER J | Chief Legal and Admin. Officer | 01 Jul 2024 | Sale | 666 | 8 | 5,328 | D |
17 Jun 2024 20:28 | ALHC | Alignment Healthcare Inc | MARGOLIS JEFFREY H | Director | 14 Jun 2024 | Sale | 1,200 | 8.06 | 9,672 | I |
17 Jun 2024 20:29 | ALHC | Alignment Healthcare Inc | JOYCE CHRISTOPHER J | Chief Legal and Admin. Officer | 14 Jun 2024 | Sale | 16,000 | 8.0124 | 128,198 | D |
14 Jun 2024 17:49 | ALHC | Alignment Healthcare Inc | MARONEY DAWN CHRISTINE | President, Markets | 12 Jun 2024 | Sale | 20,000 | 8.21 | 164,200 | D |
18 Jun 2024 16:16 | ALKT | ALKAMI TECHNOLOGY Inc | HILL W BRYAN | Chief Financial Officer | 17 Jun 2024 | Sale | 100,000 | 25.7199 | 2,571,990 | D |
10 Jun 2024 07:43 | ALKT | ALKAMI TECHNOLOGY Inc | BOHANON STEPHEN | Chief Strategy & Product Offr. | 06 Jun 2024 | Sale | 2,711 | 26.8 | 72,655 | D |
10 Jun 2024 07:43 | ALKT | ALKAMI TECHNOLOGY Inc | BOHANON STEPHEN | Chief Strategy & Product Offr. | 06 Jun 2024 | Sale | 19,460 | 26.8861 | 523,204 | D |
02 Jul 2024 17:00 | ALLK | Allakos Inc | RADFORD HARLAN BAIRD | Chief Financial Officer | 28 Jun 2024 | Sale | 87,064 | 1.01 | 87,935 | D |
20 Jun 2024 16:31 | ALLO | Allogene Therapeutics Inc | MESSEMER DEBORAH M. | Director | 18 Jun 2024 | Sale | 18,641 | 2.2793 | 42,488 | D |
03 Jul 2024 21:30 | ALMS | ALUMIS Inc | TANANBAUM JAMES B. | Director , 10% | 01 Jul 2024 | Purchase | 2,187,500 | 16 | 35,000,000 | I |
03 Jul 2024 21:30 | ALMS | ALUMIS Inc | TANANBAUM JAMES B. | Director , 10% | 01 Jul 2024 | Purchase | 312,500 | 16 | 5,000,000 | I |
03 Jul 2024 21:30 | ALMS | ALUMIS Inc | FORESITE CAPITAL MANAGEMENT V, LLC | 10% | 01 Jul 2024 | Purchase | 2,187,500 | 16 | 35,000,000 | I |
03 Jul 2024 21:31 | ALMS | ALUMIS Inc | FORESITE LABS, LLC | 10% | 01 Jul 2024 | Purchase | 2,187,500 | 16 | 35,000,000 | I |
03 Jul 2024 21:30 | ALMS | ALUMIS Inc | FORESITE CAPITAL MANAGEMENT V, LLC | 10% | 01 Jul 2024 | Purchase | 312,500 | 16 | 5,000,000 | I |
03 Jul 2024 21:31 | ALMS | ALUMIS Inc | FORESITE LABS, LLC | 10% | 01 Jul 2024 | Purchase | 312,500 | 16 | 5,000,000 | I |
18 Jun 2024 06:03 | ALNT | ALLIENT INC | TZETZO NICOLE R | Director | 14 Jun 2024 | Purchase | 300 | 24.67 | 7,401 | I |
18 Jun 2024 06:03 | ALNT | ALLIENT INC | TZETZO NICOLE R | Director | 14 Jun 2024 | Purchase | 124 | 25.22 | 3,127 | I |
18 Jun 2024 06:03 | ALNT | ALLIENT INC | TZETZO NICOLE R | Director | 13 Jun 2024 | Purchase | 176 | 25.37 | 4,465 | I |
27 Jun 2024 16:04 | ALNY | ALNYLAM PHARMACEUTICALS Inc | SCHULMAN AMY W | Director | 25 Jun 2024 | Sale | 8,500 | 240 | 2,040,000 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 25 Jun 2024 | Sale | 125 | 235.19 | 29,399 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 25 Jun 2024 | Sale | 138 | 234.66 | 32,383 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 25 Jun 2024 | Sale | 86 | 233.53 | 20,084 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 25 Jun 2024 | Sale | 161 | 232.54 | 37,439 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 25 Jun 2024 | Sale | 74 | 231.59 | 17,138 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 25 Jun 2024 | Sale | 227 | 229.93 | 52,194 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 25 Jun 2024 | Sale | 198 | 229.06 | 45,354 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 25 Jun 2024 | Sale | 96 | 228.3 | 21,917 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 25 Jun 2024 | Sale | 26 | 226.82 | 5,897 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 25 Jun 2024 | Sale | 13 | 225.55 | 2,932 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 25 Jun 2024 | Sale | 9 | 224.17 | 2,018 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | FITZGERALD KEVIN JOSEPH | CSO & EVP, Head of Research | 25 Jun 2024 | Sale | 45 | 221.71 | 9,977 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | TANGULER TOLGA | EVP, Chief Commercial Officer | 25 Jun 2024 | Sale | 167 | 235.19 | 39,277 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | TANGULER TOLGA | EVP, Chief Commercial Officer | 25 Jun 2024 | Sale | 185 | 234.66 | 43,412 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | TANGULER TOLGA | EVP, Chief Commercial Officer | 25 Jun 2024 | Sale | 115 | 233.53 | 26,856 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | TANGULER TOLGA | EVP, Chief Commercial Officer | 25 Jun 2024 | Sale | 216 | 232.54 | 50,229 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | TANGULER TOLGA | EVP, Chief Commercial Officer | 25 Jun 2024 | Sale | 99 | 231.59 | 22,927 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | TANGULER TOLGA | EVP, Chief Commercial Officer | 25 Jun 2024 | Sale | 304 | 229.93 | 69,899 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | TANGULER TOLGA | EVP, Chief Commercial Officer | 25 Jun 2024 | Sale | 266 | 229.06 | 60,930 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | TANGULER TOLGA | EVP, Chief Commercial Officer | 25 Jun 2024 | Sale | 129 | 228.3 | 29,451 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | TANGULER TOLGA | EVP, Chief Commercial Officer | 25 Jun 2024 | Sale | 34 | 226.82 | 7,712 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | TANGULER TOLGA | EVP, Chief Commercial Officer | 25 Jun 2024 | Sale | 18 | 225.55 | 4,060 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | TANGULER TOLGA | EVP, Chief Commercial Officer | 25 Jun 2024 | Sale | 13 | 224.17 | 2,914 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | POULTON JEFFREY V. | EVP, Chief Financial Officer | 25 Jun 2024 | Sale | 167 | 235.19 | 39,277 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | TANGULER TOLGA | EVP, Chief Commercial Officer | 25 Jun 2024 | Sale | 59 | 221.71 | 13,081 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | POULTON JEFFREY V. | EVP, Chief Financial Officer | 25 Jun 2024 | Sale | 185 | 234.66 | 43,412 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | POULTON JEFFREY V. | EVP, Chief Financial Officer | 25 Jun 2024 | Sale | 115 | 233.53 | 26,856 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | POULTON JEFFREY V. | EVP, Chief Financial Officer | 25 Jun 2024 | Sale | 99 | 231.59 | 22,927 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | POULTON JEFFREY V. | EVP, Chief Financial Officer | 25 Jun 2024 | Sale | 216 | 232.54 | 50,229 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | POULTON JEFFREY V. | EVP, Chief Financial Officer | 25 Jun 2024 | Sale | 304 | 229.93 | 69,899 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | POULTON JEFFREY V. | EVP, Chief Financial Officer | 25 Jun 2024 | Sale | 266 | 229.06 | 60,930 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | POULTON JEFFREY V. | EVP, Chief Financial Officer | 25 Jun 2024 | Sale | 129 | 228.3 | 29,451 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | POULTON JEFFREY V. | EVP, Chief Financial Officer | 25 Jun 2024 | Sale | 34 | 226.82 | 7,712 | D |
26 Jun 2024 16:26 | ALNY | ALNYLAM PHARMACEUTICALS Inc | POULTON JEFFREY V. | EVP, Chief Financial Officer | 25 Jun 2024 | Sale | 18 | 225.55 | 4,060 | D |
* D/I = Direct / Indirect
* 10% = Entity with 10% or higher ownership stake
* A = Amendment Filing (SEC Form 4/A)